Candel Therapeutics, Inc. (CADL) Financial Statements (2024 and earlier)

Company Profile

Business Address 117 KENDRICK STREET
NEEDHAM, MA 02494
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments70,05882,642
Cash and cash equivalents70,05882,642
Other undisclosed current assets1,8872,303
Total current assets:71,94584,945
Noncurrent Assets
Operating lease, right-of-use asset1,056 
Property, plant and equipment4,4243,836
Restricted cash and investments266 
Other noncurrent assets  424
Other undisclosed noncurrent assets  
Total noncurrent assets:5,7464,260
TOTAL ASSETS:77,69189,205
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,1035,028
Accounts payable3801,590
Accrued liabilities4,7233,438
Debt  
Other liabilities48334
Other undisclosed current liabilities464 
Total current liabilities:5,6155,362
Noncurrent Liabilities
Long-term debt and lease obligation20,850 
Long-term debt, excluding current maturities20,850 
Liabilities, other than long-term debt1,630894
Deferred revenue144 
Deferred rent credit  894
Operating lease, liability1,486 
Other undisclosed noncurrent liabilities1,88218,812
Total noncurrent liabilities:24,36219,706
Total liabilities:29,97725,068
Equity
Equity, attributable to parent47,71464,137
Common stock290286
Treasury stock, value(448) 
Additional paid in capital146,961144,146
Accumulated deficit(99,089)(80,295)
Total equity:47,71464,137
TOTAL LIABILITIES AND EQUITY:77,69189,205

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues125125
Gross profit:125125
Operating expenses(34,847)(25,851)
Operating loss:(34,722)(25,726)
Nonoperating income (expense)15,928(10,398)
Investment income, nonoperating(442)1,023
Interest and debt expense  
Loss from continuing operations:(18,794)(36,124)
Loss before gain (loss) on sale of properties:(36,124)
Net loss:(18,794)(36,124)
Other undisclosed net income attributable to parent  
Net loss available to common stockholders, diluted:(18,794)(36,124)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(18,794)(36,124)
Comprehensive loss, net of tax, attributable to parent:(18,794)(36,124)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: